



32 Sheridan Street
Boston, MA 02130
phone: 617.390.2584
fax: 617.390.2799

www.taepusa.org

Robert Greenwald
Project Director

TAEP Coordinating Committee:

National Association of
People with AIDS

Title II Community
AIDS Network

Project Inform

The AIDS Institute

AIDS Foundation
of Chicago

HIV Medicine Association

American Academy of
HIV Medicine

National Alliance of
State and Territorial
AIDS Directors

Bristol-Myers Squibb

Hoffman-LaRoche

GlaxoSmithKline

Abbott Laboratories

The Treatment Access
Expansion Project (TAEP)
is a health care access projects
of the HIV/AIDS community,
health care providers and the
pharmaceutical industry.

An Alphabetized List of HIV Research, Studies & Reports

Bhattacharya, J., Goldman, D., Sood, N. (2004). The link between public and private insurance and HIV-related mortality. Journal of Health Economics, 22, 1105-1122.

Bing, E.G., Kilborune, A.M., Brooks, R.A., et al. (1999). Protease inhibitor use among a community sample of people with HIV disease. Journal of Acquired Immune Deficiency Syndromes, 20(5), 474-480.

Bozzette, S.A., Joyce, G., McCaffrey, D.F., et al. (2001). Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. New England Journal of Medicine, 344, 817-823.

Bozzette, S.A., Berry, S.H., Duan, N., et al. (1998). The care of HIV-infected adults in the United States. New England Journal of Medicine, 339, 1897-1904.

Chapko, M.L., & Hedrick, S. (1999). Cost as a study outcome: sensitivity of study conclusions to the method of estimating cost. Medical Care 37(4) VA SUPPLEMENTS, AS37-AS44.

Conviser, R., Murray, M., & Lau, D. (2000). Medicaid managed care reimbursement for HIV and its implications for access to care. American Journal of Managed Care, 6, 990-999.

Cunningham, P. Affording Prescription Drugs: Not just a problem for the elderly. Center for Studying Health System Change, Research Report No. 5, April 2002.

Cunningham, P. Prescription Drug Access: Not just a Medicare problem. Center for Studying Health System Change, Issue Brief 51, April 2002.

Fang, C., Hsu, H., Twu, S., et al. (2004). Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. Journal of Infectious Diseases, 190, 879-885.

Freedberg, K.A., Losina, E., Weinstein, M.C., et al. (2001). The cost-effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine, 3, 824-31.

Freedberg, K.A., et al. (1998). The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA, 279, 130-136.

Gebo, K.A., Chaisson, R.E., Folkemer, J.G., et al. (1999). Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS, 13, 963-969.

Goldman, D.P, Joyce, G.F., Escarce, J.J. et al. (2004). Pharmacy benefits and the use of drugs by the chronically ill. JAMA, 291, 2344-2350.

Haber, S., Mitchell, J., & McNeill, A. Using premiums to finance care for the uninsured: lessons from the Oregon health plan, presented at Academy for Health Services Research and Health Policy Annual Meeting, 2000, cited in Ku, 2003, *supra* n. 15.

Hellinger, F.J. & Fleishman, J.A. (2000). Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. Journal of Acquired Immune Deficiency Syndromes, 24(2), 182-188.

Hellinger, F.J. (1998). Cost and financing of care for persons with HIV disease: an overview. Health Care Financing Review, 19(3), 5-18.

Holohan, J., Coughin, T., Bovbjerg, R., Hill, I., Ormond, B., & Zuckerman, S. (2004). State responses to budget crisis in 2004: an overview of ten states—overview and case studies. Kaiser Commission on Medicaid and the Uninsured. Available at <http://www.kff.org/kcmu>.

Hudman, J. & O'Malley, M. (2003). Health insurance premiums and cost-sharing: findings from the research on low-income populations. The Kaiser Commission on Medicaid and the Uninsured. Available at: <http://www.kff.org/kcmu>.

The HIV Research Network. (1999). Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. Journal of Acquired Immune Deficiency Syndromes, 30(1).

Iezzoni, L.I., Ayanian, J.Z., Bates, D.W., & Burstin, H.R. (1998). Paying more fairly for Medicare capitated care. New England Journal of Medicine, 339(26), 1933-1938.

IOM (Institute of Medicine) (2004). Public financing and delivery of HIV/AIDS care: securing the legacy of Ryan White. Available at: <http://www.nap.edu/openbook/0309092280/html/3.html>.

Kahn, J.K., Haile, B., Kates J., & Chang S. (2001). Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. American Journal of Public Health, 91(9), 1464-1471.

Keiser, P., Kvanli, M.B., & Turner, D. (1999). Protease inhibitor-based therapy is associated with decreased HIV-related health care cost in men treated at a Veterans Administration hospital. Journal of Acquired Immune Deficiency Syndromes, 20(1), 28-33.

Kitahata, M.M., Van Rompaey, S.E., & Shields, A.W. (2001). Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 24(2), 106-114.

Ku, L. (2003). Charging the poor more for health care: cost-sharing in Medicaid. Center on Budget and Policy Priorities, May 2003.

Ku, L. & Coughlin, T. (1999) Sliding-scale premium health insurance programs: four states' experiences. Inquiry, 36, winter edition, 471-480.

Lapins, D.L., Urdaneta, M.E., Barrett, J., et al. (2000). Cost of care for HIV infection in a managed care population from 1995-1997. American Journal of Managed Care, 6, 973-981.

Latz, M.H., Cunningham, W.M., & Mor, V. (2000). Prevalence and predictors of unmet need for supportive services among HIV-infected persons: impact of case management. Medical Care, 38, 58-69.

Matthews, C.M., McCutchan, J.A., & Asch, S. (2000). National estimates of HIV-related symptoms prevalence from the HIV cost and services utilization study. Medical Care, 38, 750-762.

Menke, R.J., Rabeneck, R., & Hartigan, P.M. (2000). Clinical and socioeconomic determinants of health care use among HIV-infected patients in the department of Veterans Affairs. Inquiry, 37, 61-74.

Mitchell, J.M., & Anderson, K.H. (2000). Effects of case management and new drugs on Medicaid AIDS spending. Health Affairs, July/August, 233-243.

Moore, R.D., & Chaisson, R.E. (1997). Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. Journal of Acquired Immune Deficiency Syndromes, 14(3), 223-31.

Porco, T.C., Martin, J.N., et al. (2004). Decline in HIV infectivity following the introduction of highly active antiretroviral treatment. AIDS, Jan 2, 18(1), 81-88

Rabeneck L., Menke, T., & Wray, N.P. (1999). How good are US studies of HIV costs of care? Medical Care, (8), 748-59.

Reis, P.D. (1999). Comprehensive HIV services under a capitated reimbursement system: AIDS Healthcare Foundation. American Journal of Managed Care, 5, 1450-1456.

Rodgers, J. & Yip, R. (2003). An analysis of the Early Treatment of HIV Act: Prepared for the Treatment Access Expansion Project. PricewaterhouseCoopers. Available at: www.taepusa.org.

Schackman, B.R., Goldie, S.J., Weinstein, M.C., Losina, E., Zhang, H., & Freedberg, K.A. (2001). Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. American Journal of Public Health, (91)9, 1456-1463.

Shapiro, M.F.; Morton, S.C.; McCaffey, D.F. et al. (1999). Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. Journal of the American Medical Association, 281, 2305-2315.

Smith, V., Ramesh, R., Gifford, K., Ellis, E., & Wachino, V., (2004). States respond to fiscal pressures: A 50-state update of state Medicaid spending growth and cost-containment actions. Kaiser Commission on Medicaid and the Uninsured. Available at: <http://www.kff.org/kcmu>.

Smith, V., Ramesh, R., Gifford, K., Ellis, E., & Wachino, V., States respond to fiscal pressure: state Medicaid spending growth and cost containment in fiscal years 2003 and 2004—results from a 50-state survey (2003). Kaiser Commission on Medicaid and the Uninsured. Available at: <http://www.kff.org/kcmu>.

Steinbrook, R. (2001). Providing antiretroviral therapy for HIV infection. New England Journal of Medicine, 344, 844-845.

Stuart, B. & Zacker, C. (1999). Who bears the burden of Medicaid drug copayment policies? Health Affairs, 18(2), 201-212.

Tamblyn, R. et al. (2001). Adverse events associated with prescription drug cost-sharing among poor and elderly Persons,” Journal of the American Medical Association, Vol. 285(4), 421-429.

U.S. General Accounting Office. Medicaid and SCHIP: States’ Enrollment and Payment Policies Can Affect Children’s Access to Care, GAO-01-883, September 2001.

U.S. General Accounting Office. State Pharmacy Programs: Assistance Designed to Target Coverage and Stretch Budgets, HEHS-00-162, September 2000.

Valenti, V.M. (2000). Improving Outcomes and Managing Costs of Care: from the XIII International AIDS Conference. AIDS Read, 10(8), 460-464.

Weinstein, M.C., Goldie, S.J., Losina, E., Cohen, C.J., Baxter, J.D., Zhang, H., Kimmel, A.D., & Freedberg, K.A. (2001). Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Annals of Internal Medicine, 134(6), 440-450.